Diatom species fluxes in the seasonally ice-covered Antarctic Zone:. New data from offshore Prydz Bay and comparison with other regions from the eastern Antarctic and western Pacific sectors of the Southern Ocean

The Antarctic Zone, the southernmost belt of the Antarctic Circumpolar Current, plays an important role in the control of atmospheric carbon dioxide concentrations. In the last decade, a number of studies have highlighted the importance of diatom assemblage composition in influencing the magnitude of the organic carbon and biogenic silica fluxes exported out of the mixed layer in Southern Ocean ecosystems. Here we investigate the relationship between the makeup of the diatom assemblage, organic carbon and biogenic silica export and several significant environmental parameters using sediment trap records deployed in different sectors of the Antarctic Zone. The study is divided in two parts. We first present unpublished diatom species flux data collected by a sediment trap in the offshore waters of Prydz Bay (Station PZB-1) over a year. The results of this study revealed a major export peak of diatom valves in Austral summer and two small unexpected secondary flux pulses dining full winter conditions. The summer diatom sinking assemblages were largely composed of small and rapidly dividing species such as Fragilariopsis cylindrus, Fragilariopsis curta and Pseudo-nitzschia lineola, while winter assemblages were dominated by Fragilariopsis kerguelensis most reflecting its persistent strategy and selective preservation. In the second part of the study, we compare the annual diatom assemblage composition and biogeochemical fluxes of Station PZB-1 with flux data documented in previous sediment trap studies conducted in other sectors of the Antarctic Zone in order to investigate how diatom floristics influence the composition and magnitude of particle fluxes in the Antarctic Zone. The lack of correlation between the annual diatom valve, organic carbon and biogenic silica fluxes across stations indicates that other factors aside from diatom abundance play a major role in the carbon and silica export in AZ. Among these factors, the composition of the diatom assemblage appears to be critical, as suggested by the strong and significant correlation between Bio-SiO2 and the valve fluxes of F. kerguelensis alone, that this species is the main Bio-SiO2 vector from the surface layer to the deep ocean in the AZ waters, regardless of its relative abundance. Lastly, the good correlation between the annual fluxes of the group of small Fragilariopsis species with satellite-derived chlorophyll-a concentration estimates over the study stations, suggest that high abundances of these species in the Southern Ocean paleorecords could be used as a proxy of high algal biomass accumulation.NSFNational Science Foundation (NSF) [OPP-9726186]CCMAR [PEstC/MAR/LA0015/2013]info:eu-repo/semantics/publishedVersio

A new perspective of the Alboran Upwelling System reconstruction during the Marine Isotope Stage 11: A high-resolution coccolithophore record

A high-resolution study of the MIS 12/MIS 11 transition and the MIS 11 (430–376 kyr) coccolithophore assemblages at Ocean Drilling Program Site 977 was conducted to reconstruct the palaeoceanographic and climatic changes in the Alboran Sea from the variability in surface water conditions. The nannofossil record was integrated with the planktonic oxygen and carbon stable isotopes, as well as the Uk'37 Sea Surface Temperature (SST) at the studied site during the investigated interval. The coccolithophore primary productivity, reconstructed from the PPP (primary productivity proxy = absolute values of Gephyrocapsa caribbeanica + small Gephyrocapsa group) revealed pronounced fluctuations, that were strongly associated with variations in the intensity of the regional Alboran Upwelling System. The comparison of the nannoplankton record with opal phytolith content for the studied site and the already available pollen record at the nearby Integrated Ocean Drilling Program Site U1385, suggests an association of the upwelling dynamics with the variability of the North Atlantic Oscillation-like (NAO-like) phase. High PPP during positive (+) NAO-like phases is the result of intensified upwelling, owing to the complete development of the surface hydrological structures at the Alboran Sea. This scenario was identified during the MIS 12/MIS 11 transition (428-422 kyr), the late MIS 11c (405-397 kyr), and MIS11 b to MIS 11a (397-376 kyr). Two short-term minima in the PPP and SST were observed during MIS 11 b and were coeval with the North Atlantic Heinrich-type (Ht) events Ht3 (∼390 kyr) and Ht2 (∼384 kyr). Increased abundance of the subpolar Coccolithus pelagicus subsp. pelagicus and Gephyrocapsa muellerae was consistent with the inflow of cold surface waters into the Mediterranean Sea during the Ht events. Lowered PPP during negative (−) NAO-like phases is the result of moderate upwelling by the incomplete development of surface hydrological structures at the Alboran Sea. This scenario is expressed during the early MIS 11c (422-405 kyr). Overall, the results of our study provide evidence of the important role of atmospheric circulation patterns in the North Atlantic region for controlling phytoplankton primary production and oceanographic circulation dynamics in the Western Mediterranean during MIS 11

Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial

Background: Patent foramen ovale (PFO) is a contributor to embolic stroke of undetermined source (ESUS). Subgroup analyses from previous studies suggest that anticoagulation could reduce recurrent stroke compared with antiplatelet therapy. We hypothesised that anticoagulant treatment with rivaroxaban, an oral factor Xa inhibitor, would reduce the risk of recurrent ischaemic stroke compared with aspirin among patients with PFO enrolled in the NAVIGATE ESUS trial. Methods: NAVIGATE ESUS was a double-blinded, randomised, phase 3 trial done at 459 centres in 31 countries that assessed the efficacy and safety of rivaroxaban versus aspirin for secondary stroke prevention in patients with ESUS. For this prespecified subgroup analysis, cohorts with and without PFO were defined on the basis of transthoracic echocardiography (TTE) and transoesophageal echocardiography (TOE). The primary efficacy outcome was time to recurrent ischaemic stroke between treatment groups. The primary safety outcome was major bleeding, according to the criteria of the International Society of Thrombosis and Haemostasis. The primary analyses were based on the intention-to-treat population. Additionally, we did a systematic review and random-effects meta-analysis of studies in which patients with cryptogenic stroke and PFO were randomly assigned to receive anticoagulant or antiplatelet therapy. Findings: Between Dec 23, 2014, and Sept 20, 2017, 7213 participants were enrolled and assigned to receive rivaroxaban (n=3609) or aspirin (n=3604). Patients were followed up for a mean of 11 months because of early trial termination. PFO was reported as present in 534 (7·4%) patients on the basis of either TTE or TOE. Patients with PFO assigned to receive aspirin had a recurrent ischaemic stroke rate of 4·8 events per 100 person-years compared with 2·6 events per 100 person-years in those treated with rivaroxaban. Among patients with known PFO, there was insufficient evidence to support a difference in risk of recurrent ischaemic stroke between rivaroxaban and aspirin (hazard ratio [HR] 0·54; 95% CI 0·22–1·36), and the risk was similar for those without known PFO (1·06; 0·84–1·33; pinteraction=0·18). The risks of major bleeding with rivaroxaban versus aspirin were similar in patients with PFO detected (HR 2·05; 95% CI 0·51–8·18) and in those without PFO detected (HR 2·82; 95% CI 1·69–4·70; pinteraction=0·68). The random-effects meta-analysis combined data from NAVIGATE ESUS with data from two previous trials (PICSS and CLOSE) and yielded a summary odds ratio of 0·48 (95% CI 0·24–0·96; p=0·04) for ischaemic stroke in favour of anticoagulation, without evidence of heterogeneity. Interpretation: Among patients with ESUS who have PFO, anticoagulation might reduce the risk of recurrent stroke by about half, although substantial imprecision remains. Dedicated trials of anticoagulation versus antiplatelet therapy or PFO closure, or both, are warranted. Funding: Bayer and Janssen